Core Viewpoint - The company reported a stable performance in its core business for the fiscal year 2025, but faced a decline in profits due to impairment provisions related to its investment in a subsidiary [1] Financial Performance - The company achieved an operating revenue of 565 million yuan, representing a year-on-year increase of 1.20% [1] - The total profit amounted to 60.27 million yuan, reflecting a year-on-year decrease of 36.97% [1] - The net profit attributable to the parent company was 48.21 million yuan, down 36.26% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 33.38 million yuan, showing a year-on-year decline of 53.13% [1]

Core Viewpoint - Jiet Bio announced that it expects to achieve a total operating revenue of 565.36 million yuan in 2025, representing a year-on-year growth of 1.20% and a net profit attributable to the parent company of 48.21 million yuan [2] Financial Performance - The projected total operating revenue for 2025 is 565.36 million yuan [2] - The expected net profit attributable to the parent company is 48.21 million yuan [2] - The year-on-year growth rate for total operating revenue is 1.20% [2]

Group 1 - The company, JieTe Bio, reported an operating income of approximately 565 million yuan for the year 2025, representing a year-on-year increase of 1.2% [1] - The net profit attributable to shareholders of the listed company was 48.21 million yuan, showing a year-on-year decrease of 36.26% [1] - The basic earnings per share were 0.35 yuan, which is a decrease of 36.36% compared to the previous year [1]

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2026-012 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | （一）名称：广州蓝勃生物科技有限公司 （二）统一社会信用代码：91440116797381778C （三）类型：有限责任公司（自然人投资或控股） 广州洁特生物过滤股份有限公司 关于对参股公司计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 广州洁特生物过滤股份有限公司（以下简称"公司"）于2021年10月9日以自有 资金对广州蓝勃生物科技有限公司（以下简称"蓝勃生物"）增资3,000万元，增资 后公司持有蓝勃生物15.0007%股份，蓝勃生物主要从事实验分析仪器制造。 一、参股公司蓝勃生物基本情况 （四）住所：广州市黄埔区瑞和路39号H6栋425-433房 （五）法定代表人：王治才 （六）注册资本：2,000万元 （七）成立日期：2007年1月25日 （八）经营范围：实验分析仪器制造;商品批发贸易（许可审批类商品除外）; ...

| 证券代码：688026 | 证券简称：洁特生物 | 公告编号：2026-011 | | --- | --- | --- | | 转债代码：118010 | 转债简称：洁特转债 | | 广州洁特生物过滤股份有限公司 关于会计政策变更的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 广州洁特生物过滤股份有限公司（以下简称"公司"）本次会计政策变更的内容 是根据中国证券监督管理委员会、财政部发布的有关规定进行的，无需提交董事 会及股东会审议，不会对公司的财务状况、经营成果和现金流量产生重大影响， 亦不存在损害公司及中小股东利益的情形。 一、会计政策变更概述 （一）变更的原因及变更日期 2025年7月18日，中国证券监督管理委员会发布《监管规则适用指引——会计 类第5号》（以下简称"会计类5号"），对财政部发布的《企业会计准则第18号—— 所得税》等关于递延所得税初始确认豁免相关规定给予进一步的处理意见。会计 类5号指出，监管实践发现，部分发行可转换债券的公司对于是否应确认发行可转 换债券相关递延所得税负债， ...

Financial Performance - The company achieved total revenue of RMB 55,700.74 million in 2024, representing a year-on-year increase of 20.28%[4] - Operating profit reached RMB 9,733.00 million, up 146.76% compared to the previous year[4] - Net profit attributable to the parent company was RMB 7,381.42 million, reflecting a growth of 112.18% year-on-year[4] - The basic earnings per share increased to RMB 0.53, a rise of 112.00% from the previous year[4] Asset Management - The company's total assets at the end of 2024 were RMB 170,580.67 million, a 4.90% increase from the beginning of the period[4] Profitability - The gross profit margin improved by 10.1 percentage points to 40.7% due to cost optimization and increased sales volume[11] Product Development - The company developed several new products, including storage bags and cell culture bags, enhancing its product portfolio[9] Brand Promotion - The company participated in over 30 domestic and international life science and biotechnology exhibitions, boosting brand exposure[10] - The company plans to continue expanding its international brand promotion in regions such as Europe, the Middle East, and Southeast Asia[11] Market Environment - The company is benefiting from favorable policies in the domestic market, particularly in the life sciences sector, which is experiencing a recovery[9]

Core Viewpoint - Jiet Bio reported a revenue of 565 million yuan for the fiscal year 2025, reflecting a year-on-year growth of 1.20%, while net profit decreased by 36.26% to 48.21 million yuan [1] Financial Performance - The company's operating profit, total profit, net profit attributable to shareholders, net profit attributable to shareholders after deducting non-recurring gains and losses, and basic earnings per share all experienced a year-on-year decline [1] - The decline in profitability is primarily attributed to the impairment provision for long-term equity investment in Guangzhou Lanbo Biotechnology Co., Ltd. and increased selling and administrative expenses due to efforts to explore new markets and business areas [1]

Core Viewpoint - Jiet Bio is involved in a mold procurement contract dispute, with the outcome potentially impacting the company's financial status. The company anticipates a revenue growth rate of over 30% in 2026, with new product revenue expected to account for over 25% of total revenue [1][2]. Recent Events - The court announced a retrial judgment on February 4, 2026, regarding the mold procurement contract dispute with Shenzhen Hesheng Medical Technology Co., Ltd. The contract was terminated, but the court rejected Jiet Bio's claims for refund and compensation. The company plans to appeal, and the outcome may affect its financial situation. The dispute involves over 10 million yuan, and the company has fully provisioned for related prepayments as bad debt [2]. Performance and Operations - According to management statements from January 2026, Jiet Bio expects overall revenue growth to remain above 30% in 2026, with new product revenue share targeted to exceed 25%. The company aims to establish a dual-driven growth model of "core product steady growth and new product rapid growth." In the first three quarters of 2025, new product sales reached 120 million yuan, a year-on-year increase of 120%, focusing on areas such as cell and gene therapy (CGT) consumables and high-end filtration materials. The company emphasizes increasing R&D investment to transition into a "comprehensive solution provider" [3]. Company Status - In a February 2026 announcement, Jiet Bio stated that the cash dividend ratio for the next three years (2024-2026) will not be less than 30% of the distributable profits for the year. Since its listing, the company has distributed over 100 million yuan in dividends and has implemented share buybacks to provide steady returns to investors. In the latest ESG rating on October 31, 2025, Jiet Bio received a CC rating from Huazheng Index, ranking 23rd in the life sciences tools and services industry. Although this is not a recent event, ESG factors may influence long-term investor interest, and the company needs to continuously improve its environmental, social, and governance performance [4].

Core Viewpoint - As of February 6, 2026, Jiet Bio (688026) has seen a stock price increase of 2.56% from the previous week, closing at 18.4 yuan, with a total market capitalization of 2.583 billion yuan [1] Group 1: Company Stock Performance - Jiet Bio's stock reached a weekly high of 18.68 yuan and a low of 17.77 yuan during the week [1] - The company ranks 123rd out of 129 in the medical device sector and 4926th out of 5186 in the overall A-share market by market capitalization [1] Group 2: Share Buyback Announcement - The company announced a share buyback plan with a total fund of no less than 15 million yuan and no more than 30 million yuan, with a maximum buyback price of 25.32 yuan per share [1] - As of January 31, 2026, Jiet Bio has repurchased 272,799 shares, accounting for 0.19% of the total share capital, at an average price between 18.05 yuan and 18.43 yuan, totaling 4.9714 million yuan spent [1][3] Group 3: Legal Matters - Jiet Bio is involved in a lawsuit against Shenzhen Hesheng Medical Technology Co., regarding a contract dispute with a claim amount of 10,340,829 yuan [2] - The court ruled to terminate the contract and dismissed other claims, with the company fully provisioning for the prepaid amount as bad debt [2][3]

Trading Information - On February 5, 2026, Jiet Bio (688026) closed at 18.33 yuan, down 0.43%, with a turnover rate of 1.28% and a trading volume of 18,000 shares, amounting to a total transaction value of 33.18 million yuan [1] - On the same day, the net inflow of main funds was 4.87 million yuan, accounting for 14.67% of the total transaction value; retail investors had a net outflow of 2.87 million yuan, representing 8.64% of the total transaction value [2] Legal Matters - Jiet Bio, as the plaintiff (and counter-defendant), filed a lawsuit against Shenzhen Hesheng Medical Technology Co., Ltd. regarding a dispute over nine "Mold Procurement Contracts," with a total amount in dispute of 10,340,829.00 yuan [1] - The court ruled to terminate the nine contracts and rejected all claims from both Jiet Bio and Hesheng Medical in the retrial of the first instance [2] - Jiet Bio has fully provided for bad debts related to the advance payment to Hesheng Medical and plans to appeal the ruling, with the impact on current and future profits yet to be determined [1]